AveragePenny
7月前
$PETV PetVivo Holdings, Inc. Presenting at the 3rd Annual DealFlow Discovery Conference
https://www.accessnewswire.com/newsroom/en/biotechnology/petvivo-holdings-inc.-presenting-at-the-3rd-annual-dealflow-discovery-conference-1120122
MINNEAPOLIS, MN / ACCESS Newswire / December 23, 2025 / PetVivo Holdings, Inc. (OTCQX:PETV)(OTCID:PETVW), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.
John Lai, Chief Executive Officer of PetVivo Holdings, Inc., will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about PetVivo Holdings, Inc. and its innovative products at www.petvivo.com.
In the presentation Mr. Lai will be providing information about its lead products, Spryng® with OsteoCushion® Technology and PrecisePRP™. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
Event Details:
3rd Annual DealFlow Discovery Conference
The Borgata Hotel, Casino & Spa
Atlantic City, NJ
January 28-29, 2026
Investors interested in scheduling a meeting with the [Company Name] management team should request an investor pass to attend the conference (no cost to attend). For more information about Spryng and PrecisePRP, please contact info1@petvivo.com or visit petvivoanimalhealth.com and sprynghealth.com.
AveragePenny
8月前
$PETV PetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89%
https://www.globenewswire.com/news-release/2025/11/25/3194291/0/en/PetVivo-Launches-AI-Platform-Reducing-Veterinary-Client-Acquisition-Costs-by-50-89.html
Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market
MINNEAPOLIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced the launch of PetVivo.ai, a new artificial intelligence platform delivering a customer acquisition cost of $42.53—a 50–89% reduction compared to the $80–$400 typically spent by veterinary practices. The platform generates qualified leads for $3 per pet parent (versus $15–$45 through traditional digital advertising) and uses automated AI engagement to convert these leads into paying customers.
This launch marks a major strategic move for PetVivo Holdings as the company expands from traditional medical device sales—historically generating 30–40% margins—into a high-margin AI Software-as-a-Service (SaaS) model with 80–90% margins, recurring revenue, and significant scalability.
The Problem
Although the pet care industry now exceeds $150 billion annually, veterinary practices face a widening gap in how they reach today’s pet owners. Gen Z and Millennial pet parents account for 57% of all pet owners and expect modern digital experiences, yet many practices still depend on outdated marketing methods such as TV advertising and direct mail.
"Veterinary practices spend $80–$400 per new client depending on their marketing approach," said John Lai, Chief Executive Officer. "Our AI generates qualified leads at just $3 each and converts them automatically. In our beta program, the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53—achieving 50–89% savings without the need for promotional discounting."
The Solution
PetVivo.ai solves this problem through a suite of nine specialized AI agents operating continuously: Client Discovery, Campaign Manager, Engagement, Analytics, Content Creation, Reputation, Compliance, ROI Optimization, and Practice Integration. Together, these agents connect practices with millions of engaged pet parents through a two-sided ecosystem.
Industry-Leading Economics
The platform’s economics were validated in a 50-practice beta program:
Lead Generation: $3 per qualified pet parent (vs. $15–$45 traditional)
Customer Acquisition Cost: $42.53 blended CAC (vs. $80–$400 typical)
Beta Results: 47 new clients median over 6 months (range: 12–124)
Pricing: $1,999/month for the Professional tier
LTV/CAC Ratio: 25:1 (best-in-class)
Payback Period: 1 month
Gross Margins: 80–90%
Market Opportunity
PetVivo.ai targets 30,000 U.S. veterinary practices and more than 100,000 globally. Even conservative adoption forecasts indicate strong scaling potential:
Year 1: 500 practices ? $12M ARR
Year 3: 5,000 practices ? $180M ARR
Year 5: 10,000 practices ? $360M ARR
The Catalyst
The launch serves as a major catalyst for re-valuing the company as it transitions from traditional medical device revenue multiples (1–2x revenue) to AI SaaS multiples (15–30x revenue). Comparable companies such as Salesforce, HubSpot, Veeva Systems, and C3.ai trade at median multiples near 15x, suggesting potential 5–10x valuation upside as PetVivo.ai scales.
"We are currently valued as a medical device company while building an AI SaaS platform with far superior economics," added Mr. Lai. "As revenue grows, we expect meaningful valuation re-rating."
Competitive Advantages
PetVivo.ai holds a first-mover advantage with no direct AI competitors, strong two-sided network effects, and existing relationships with 1,200 veterinary clinic distributors (with plans to target in excess of an additional 7,000). Deep integrations with practice management systems further accelerate adoption and reduce onboarding friction.
Commercial Launch
Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups at www.petvivo.ai, a 14-day free trial, three pricing tiers, and both direct-sales and self-service onboarding.
AveragePenny
8月前
$PETV PetVivo Holdings Announces Digital Landia’s Publication of Technical Whitepaper Validating AgenticPet AI Framework Under Exclusive 10-Year Licensing Agreement
https://www.globenewswire.com/news-release/2025/11/17/3189065/0/en/PetVivo-Holdings-Announces-Digital-Landia-s-Publication-of-Technical-Whitepaper-Validating-AgenticPet-AI-Framework-Under-Exclusive-10-Year-Licensing-Agreement.html
Comprehensive Documentation Confirms Production-Ready Architecture for PetVivo’s Veterinary Platform Launching Q1 2026
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced that its exclusive AI technology partner, Digital Landia Holding Corp., has published a comprehensive technical whitepaper documenting the AgenticPet AI Framework powering PetVivo's B2B veterinary-practice platform.
The whitepaper validates the technical foundation underlying PetVivo's October 2025 exclusive 10-year white-label licensing agreement, providing veterinary professionals, investors, and industry stakeholders with detailed visibility into the multi-agent artificial intelligence architecture that enables transformative clinical and economic benefits for veterinary practices.
TECHNICAL DUE DILIGENCE VALIDATED
"Our October announcement represented months of rigorous technical due diligence," stated John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "We don't partner lightly—especially on decade-long agreements. Today's whitepaper demonstrates exactly what we evaluated: a production-ready AI framework with genuine clinical utility, protected intellectual property, and enterprise-grade architecture capable of serving our entire veterinary network. This isn't a proof of concept; it's fully deployable infrastructure."
FRAMEWORK CAPABILITIES ALIGNED WITH VETERINARY NEEDS
The published whitepaper details technical capabilities that directly address modern veterinary practice challenges, including a 90 to 98 percent reduction in client acquisition costs through seamless pet-parent data flows; universal diagnostic assistance with nine specialized AI agents available across entire clinic patient bases; and enhanced Gen Z market access through a mobile-first consumer experience aligned with digital-native expectations.
INTELLECTUAL PROPERTY PROTECTION
The whitepaper reveals five patent-pending innovations protecting the AgenticPet framework’s core functionality, providing PetVivo with significant competitive advantages under its exclusive 10-year licensing agreement: (1) distributed agent-certification systems; (2) swarm-intelligence coordination protocols; (3) privacy-preserving health-data synthesis; (4) real-time veterinary-integration layers; and (5) adaptive learning pipelines.
ENTERPRISE-READY ARCHITECTURE
The technical documentation demonstrates an architecture specifically designed for professional veterinary-practice requirements, including end-to-end encryption, blockchain audit trails, HIPAA-aligned privacy frameworks, API specifications for practice-management-system integration, automated health-history uploads, and cloud-native infrastructure ensuring over 99.9 percent uptime reliability.
"The whitepaper makes clear that Digital Landia built this framework for veterinarians—not just pet parents," noted Mr. Lai. "The enterprise-grade security, seamless integration specifications, and clinical workflow design demonstrate a deep understanding of veterinary practice operations."
DISTRIBUTION NETWORK READY
PetVivo's established product distribution network, including its partnership with Veterinary Growth Partners (VGP), a prominent veterinary association that has more than 7,300 veterinary professional members, and its established relationships with over 1,000 clinics already using its existing SPRYNG® and PrecisePRP™ product lines, positions the Company to rapidly deploy the AgenticPet platform across a rapidly expanding veterinary industry.
STRATEGIC RATIONALE FOR EXCLUSIVE AGREEMENT
PetVivo's exclusive 10-year licensing structure reflects its confidence in the framework’s competitive positioning and multiple revenue streams, including B2B subscriptions, lead-generation fees, and premium features. Platform network effects increase value as adoption grows, supported by strong demographic tailwinds as Gen Z pet ownership rises approximately 43.5 percent annually.
PARTNERSHIP MILESTONE PROGRESSION
Today's publication marks the third major milestone in the PetVivo–Digital Landia partnership: (1) the March 2025 strategic alliance announcement; (2) the October 2025 exclusive 10-year licensing agreement; and (3) the November 2025 comprehensive technical whitepaper enabling independent evaluation of the framework.
Q1 2026 DUAL-PLATFORM LAUNCH
The documented technical foundation supports a Q1 2026 commercial launch featuring Digital Landia's B2C AgenticPet app and PetVivo's B2B veterinary platform with white-labeled AI diagnostic assistance. Pre-launch registration opens in January 2026.
WHITEPAPER ACCESS
The AgenticPet AI Framework Technical Whitepaper is publicly available at: https://digital-landia.gitbook.io/agentic-pet-whitepaper/.
PetVivo encourages veterinary professionals, investors, and industry stakeholders to review this comprehensive technical documentation.
AveragePenny
8月前
$PETV Digital Landia Publishes Technical Whitepaper for AgenticPet AI Framework After One Year of Development and Stress Testing
https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/digital-landia-publishes-technical-whitepaper-for-agenticpet-ai-fram-1100917
Unlike Typical Tech Announcements, Whitepaper Documents Already Built and Validated Production System; Five Patent Pending Innovations Ahead of Q1 2026 Launch
MIAMI, FLORIDA / ACCESS Newswire / November 12, 2025 / Digital Landia Holding Corp today announced the public release of its comprehensive AgenticPet AI Framework Technical Whitepaper, marking a significant departure from industry norms by documenting a fully developed and stress tested system rather than theoretical concepts. After one full year of rigorous development, testing, and validation, the company is providing complete transparency into the multi agent architecture powering its revolutionary pet healthcare platform and validating the technology foundation behind its exclusive 10 year licensing partnership with publicly traded PetVivo Holdings, Inc. (OTCQX:PETV).
BUILT FIRST, DOCUMENTED SECOND
"We deliberately reversed the typical Silicon Valley playbook," stated Karim Quazzani, Chief Executive Officer of Digital Landia Holding Corp. "Most tech companies release whitepapers describing what they hope to build someday. We spent an entire year actually building, testing, and validating our framework before publishing a single page of documentation. This whitepaper doesn't describe vaporware or future intentions. It documents a production ready system that has undergone extensive stress testing and real world validation."
The one year development period included architectural design, multi agent system implementation, security framework validation, performance benchmarking under simulated load conditions, and integration testing with veterinary practice management systems.
TECHNICAL ARCHITECTURE REVEALED
The AgenticPet AI Framework employs a sophisticated multi agent architecture featuring nine specialized diagnostic agents operating collaboratively through swarm intelligence coordination. This distributed approach enables autonomous decision making, continuous learning, and multimodal data integration across audio, video, behavioral patterns, IoT sensors, and laboratory results.
The whitepaper provides comprehensive technical specifications including system architecture diagrams, data flow pipelines, API documentation, security protocols, and performance benchmarks validated through extensive testing over the past year.
FIVE PATENT PENDING INNOVATIONS
Digital Landia has secured intellectual property protection for five core innovations developed during the year long build process: distributed agent certification systems, swarm intelligence coordination protocols, privacy preserving health data synthesis, real time veterinary integration layers, and adaptive learning pipelines. These innovations create significant competitive advantages while enabling genuine clinical utility.
STRESS TESTED AND PRODUCTION READY
The yearlong development cycle included rigorous stress testing across multiple dimensions. Load testing simulated millions of concurrent users. Security testing validated encryption protocols and blockchain audit trails. Integration testing confirmed seamless compatibility with existing veterinary practice management systems. Performance testing verified sub second response times under real world conditions.
"Every claim in this whitepaper has been tested and validated," added Karim Quazzani. "We're not promising what we'll build. We're documenting what we've already built and proven works."
VALIDATION OF PETVIVO PARTNERSHIP
Today's publication provides technical validation for the exclusive 10 year B2B licensing agreement announced with PetVivo Holdings in October 2025. PetVivo's extensive due diligence process included hands-on evaluation of the functioning system, not just architectural concepts.
The partnership leverages Digital Landia's AgenticPet B2C freemium app alongside PetVivo's B2B veterinary platform serving over 7,300 clinics through Veterinary Growth Partners. The technical documentation demonstrates how the dual platform architecture enables frictionless data flow, universal diagnostic assistance for all veterinary patients, and dramatic cost reduction of 90 to 98 percent in client acquisition.
Q1 2026 LAUNCH TIMELINE CREDIBLE
The Q1 2026 commercial launch timeline is credible precisely because the technology already exists and has been validated. The remaining months focus on final integrations, user interface refinements, and deployment preparation rather than core technology development.
WHITEPAPER ACCESS
The AgenticPet AI Framework Technical Whitepaper is now publicly available at:
https://digital-landia.gitbook.io/agentic-pet-whitepaper/
Greengo
2年前
As a PetVivo salesman, I’d like to discuss why Spryng is a superior choice for treating osteoarthritis in dogs and cats compared to Librela. Let’s examine the facts: Librela’s Concerning Safety Profile Librela, while marketed as an effective treatment, comes with significant risks: • The FDA received over 3,800 reports of side effects through the end of 2023 • The European Medicines Agency received more than 12,300 adverse event reports since 2021 These side effects include: • Ataxia • Seizures • Neurological issues (paresis, recumbency) • Urinary incontinence • Polyuria and polydipsia • In some cases, death or euthanasia Just three weeks ago, the FDA cited Zoetis for potentially underreporting more severe side effects, raising serious concerns about the drug’s safety profile. Problems with Nerve Growth Factor Inhibition Librela’s mechanism of action, inhibiting nerve growth factor (NGF), can lead to: • Increased risk of rapidly progressive osteoarthritis • Potential for osteonecrosis • Systemic effects throughout the body, not just in affected joints • Dramatic increase in systemic oxidative stress, particularly harmful for animals in pre-arthritis and early arthritis stages Spryng: A Superior Alternative Now, let me introduce you to Spryng, a revolutionary treatment that addresses the root cause of osteoarthritis: 1. Mechanism of Action: • Provides a shock-absorbing matrix that mimics natural cartilage • Directly addresses joint mechanics, not just masking pain 2. Safety Profile: • Demonstrated excellent safety in clinical studies • No significant adverse events reported • Localized to the injected joint, minimizing systemic effects 3. Long-lasting Effects: • A single injection can provide benefits for up to 12 months or longer • Compared to Librela’s required monthly injections 4. Cost-effective: • Approximately 50% cheaper for the customer over the course of a year 5. Natural Composition: • Made from purified, naturally-derived proteins and carbohydrates • Mimics the structure and function of natural cartilage 6. Regulatory Advantage: • Classified as a veterinary medical device, not requiring FDA premarket approval 7. Versatility: • Effective for all stages of osteoarthritis • Can be used in multiple joint locations By choosing Spryng, you’re offering your patients a safer, more effective, and cost-efficient solution for managing osteoarthritis. It’s time to move beyond simply masking pain and address the underlying cause of joint issues, providing long-term relief and improved quality of life for our furry companions.
Golden Cross
7年前
News out --- PetVivo Holdings, Inc. Featured in New Research Update
Press Release | 09/26/2019
MINNEAPOLIS, MN, Sept. 26, 2019 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.
The updated report provides an overview of recent events, new initiatives, and the company’s valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed at its partner site, www.GoldmanResearch.com.
Marble Arch Research notes that, “With a number of competitive advantages in the space, a deep product pipeline and IP portfolio, combined with a clever financial model, we believe that the Company can enjoy hockey-stick type sales growth in the next 2-3 years. Plus, its new technology licensing for CBD use could prove to be a sleeper and a very profitable engine for PetVivo. Our target is based upon a 5.5x sales P/S multiple, similar to its peer group, and affirmed by a Net Present Value (NPV) calculation. In our view, the current price reflects an attractive entry point.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of eighteen patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs and horses called Kush® is scheduled for launch later this fiscal year.
The Company recently exclusively licensed its mucoadhesive technology to a strategic partner, Emerald Organic Products, Inc., for use of CBD in the human nutraceutical market. The Company will also be seeking additional licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
John Lai
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Renee
2年前
IPO$
4年前
Emerging Growth Conf
4年前
Midwestrader
6年前
whytestocks
6年前
メールアドレスで登録
